Skip to main content

A division of

Johnson & Johnson

(JNJ)

said it received a not approvable letter from the Food and Drug Administration regarding a bid to use Risperdal for treating autism.

The company,

Johnson & Johnson Pharmaceutical Research & Development

, is evaluating the FDA's letter and will determine the appropriate next steps.

Risperdal is a prescription medication approved by the FDA for bipolar disorder. The product is approved for use as therapy alone or in combination with drugs called mood stabilizers, such as lithium or valproate.

Shares of Johnson & Johnson were up 14 cents to $67.55 on the

New York Stock Exchange

.